|
Canada-0-DECALS Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Leadership | Biogen
Meet our executive leadership team Head of Corporate Affairs, Chief Communications Officer
- Chris Viehbacher - Wikipedia
In 2022, Viehbacher joined Biogen as President and Chief Executive Officer
- Biogen, on the heels of a $5. 6B buyout, turns its sights to early-stage . . .
At the beginning of 2025, Biogen CEO Christopher Viehbacher tried to temper expectations around the company’s appetite for deals Biogen, looking to diversify its core research areas, had spent $8 5 billion over the past couple years on an immunology-focused drug developer and a rare disease
- Former Sanofi head Viehbacher to become Biogen CEO
Six months after Biogen began its search for new leadership, the biotech has now named former Sanofi chief executive Christopher Viehbacher as Michel Vounatsos’ replacement, effective from 14th
- From Science to Impact with Biogen CEO Chris Viehbacher
CEO, Chris Viehbacher talks about how the company is expanding its global footprint and diversifying its pipeline, all while navigating a rapidly evolving regulatory environment The science
- Biogen to acquire Apellis for $5. 6 billion - The Boston Globe
Biogen CEO Chris Viehbacher, who joined the company in late 2022, has sought to grow its business through acquisitions, particularly in immunology Biogen acquired Human Immunology Biosciences, or
- Chris Viehbacher, Biogen Inc: Profile and Biography
Chris Viehbacher is President CEO at Biogen Inc See Chris Viehbacher's compensation, career history, education, memberships
- Christopher A. Viehbacher - NAM
Christopher A Viehbacher joined Biogen as President and Chief Executive Officer and a member of the Board of Directors in November 2022
- A New Era for Biogen and LA Biotech: Christopher Viehbacher’s Vision at . . .
Biogen CEO Christopher Viehbacher outlines a bold new vision at LABEST 2024, highlighting innovation in immunology, rare disease, and biotech leadership
- Biogen bets on $5. 6 billion buyout of Apellis in rare disease push
Biogen will buy Apellis Pharmaceuticals for about $5 6 billion, adding a promising kidney disease drug to broaden its rare-disease portfolio amid efforts to diversify beyond its slowing multiple
|
|